Literature DB >> 24220052

Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma.

Seigo Nishida1, David M Levi, Andreas G Tzakis.   

Abstract

PURPOSE OF REVIEW: Natural killer (NK) cells are innate immune lymphocytes. NK cells contribute to host antimicrobial and antitumor immunity. Liver transplantation in patients with hepatocellular carcinoma (HCC) has increased recently. The possibility of NK cell immunotherapy for liver cancer has been studied. RECENT
FINDINGS: Adoptive transfer of interleukin-2 (IL-2)-stimulated NK cells extracted from donor liver perfusate could increase an antitumor response without causing toxicity against 1-haplotype identical recipient intact tissues in patients with live donor liver transplant. Donor liver NK cells showed the most vigorous cytotoxicity against an HCC after in-vitro IL-2 stimulation, compared with donor and recipient peripheral blood NK cells and recipient liver NK cells. IL-2 stimulation led to an increased expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on liver NK cells. T-cell contamination and risk of graft-versus-host disease can be minimized with a T-cell depleting agent such as anti-CD3 antibody.
SUMMARY: Allogeneic NK cells might have an advantage for adoptive immunotherapy. Liver NK cells from a deceased donor liver can be used safely as adoptive immunotherapy under current good manufacturing practice conditions for the treatment of liver transplantation with HCC. IL-2-stimulated liver NK cells have strong cytotoxicity, express TRAIL and secret interferon-γ.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24220052     DOI: 10.1097/MOT.0000000000000024

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  7 in total

Review 1.  Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches.

Authors:  Min Yu; Zonghai Li
Journal:  Front Med       Date:  2017-08-05       Impact factor: 4.592

2.  Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.

Authors:  Min Yu; Hong Luo; Mingliang Fan; Xiuqi Wu; Bizhi Shi; Shengmeng Di; Ying Liu; Zeyan Pan; Hua Jiang; Zonghai Li
Journal:  Mol Ther       Date:  2017-12-19       Impact factor: 11.454

3.  Liver-infiltrating CD11b-CD27- NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression.

Authors:  Qiong-Fang Zhang; Wen-Wei Yin; Yang Xia; Ya-Yang Yi; Qiu-Feng He; Xing Wang; Hong Ren; Da-Zhi Zhang
Journal:  Cell Mol Immunol       Date:  2016-06-20       Impact factor: 11.530

4.  Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation: a case report.

Authors:  Silun Xie; Zhengyi Wu; Liang Zhou; Yingqing Liang; Xiaohua Wang; Lizhi Niu; Kecheng Xu; Jibing Chen; Mingjie Zhang
Journal:  Onco Targets Ther       Date:  2018-10-25       Impact factor: 4.147

Review 5.  Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications.

Authors:  Pil Soo Sung; Jeong Won Jang
Journal:  Int J Mol Sci       Date:  2018-11-19       Impact factor: 5.923

6.  Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth.

Authors:  Ahmed Lasfar; Andrew de laTorre; Walid Abushahba; Karine A Cohen-Solal; Ismael Castaneda; Yao Yuan; Kenneth Reuhl; Andrew Zloza; Elizabeth Raveche; Debra L Laskin; Sergei V Kotenko
Journal:  Oncotarget       Date:  2016-08-02

Review 7.  Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.

Authors:  Naofumi Mukaida; Yasunari Nakamoto
Journal:  World J Gastroenterol       Date:  2018-05-07       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.